trazodone has been researched along with clonazepam in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bakish, D | 1 |
| Aronson, SC; Barr, LC; Goodman, WK; McDougle, CJ; Price, LH | 1 |
| Abdelhamid, A; Annandale, JB; Lauterbach, EC | 1 |
| Chang, YY; Chen, CH; Lee, Y; Lin, CC; Lin, PY | 1 |
| Agah, E; Aghamollaii, V; Hadi, F; Mirsepassi, Z; Mousavi, SV; Tafakhori, A; Talachi, N; Tavanbakhsh, S | 1 |
2 review(s) available for trazodone and clonazepam
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Biological approaches to treatment-resistant obsessive compulsive disorder.
Topics: Behavior Therapy; Buspirone; Clonazepam; Combined Modality Therapy; Decision Trees; Drug Therapy, Combination; Electroconvulsive Therapy; Fenfluramine; Humans; Lithium; Obsessive-Compulsive Disorder; Phototherapy; Selective Serotonin Reuptake Inhibitors; Sleep Deprivation; Trazodone; Tryptophan | 1993 |
1 trial(s) available for trazodone and clonazepam
| Article | Year |
|---|---|
Safety and efficacy of melatonin, clonazepam, and trazodone in patients with Parkinson's disease and sleep disorders: a randomized, double-blind trial.
Topics: Clonazepam; Double-Blind Method; Humans; Iran; Melatonin; Parkinson Disease; Sleep Wake Disorders; Trazodone | 2022 |
6 other study(ies) available for trazodone and clonazepam
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Fluoxetine potentiation by buspirone: three case histories.
Topics: Adult; Buspirone; Clonazepam; Depressive Disorder; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Fluoxetine; Humans; Trazodone; Tryptophan | 1991 |
Posthallucinogen-like visual illusions (palinopsia) with risperidone in a patient without previous hallucinogen exposure: possible relation to serotonin 5HT2a receptor blockade.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bipolar Disorder; Clonazepam; Female; GABA Modulators; Humans; Illusions; Middle Aged; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Risperidone; Serotonin Antagonists; Trazodone | 2000 |
Tardive dystonia and tardive sensory syndrome related to trazodone: a case report.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Anxiety Disorders; Clonazepam; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Jaw; Neurologic Examination; Trazodone | 2008 |